Publication Name	World Journal of Gastroenterology
Manuscript ID	119693
Country	Spain

Category	Gastroenterology & Hepatology
Manuscript Type	Observational Study
Article Title	Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis
Manuscript Source	Invited Manuscript
All Author List	Antonio M Caballero-Mateos, Teresa Valdés-Delgado, Raúl Olmedo-Martín, Patricia Romero-Cara, María del Mar Martín-Rodríguez, Ana Lancho Muñoz, Melody Moreno-Barrueco, Raúl Gijón-Villanova, Nuria Fernández-Moreno, Francisco J Rodríguez-González, Álvaro Hernández-Martínez, Ana María Trapero-Martínez, Ana Bejarano-García, José Manuel Benitez Cantero, Francisco J Mata-Perdigón, Antonia Sáez-Díaz and Federico Argüelles-Arias
Funding Agency and Grant Number
Corresponding Author	Teresa Valdés-Delgado, Department of Gastroenterology, Virgen Macarena University Hospital, Dr. Fedriani, Seville 41009, Spain. teresavaldes4@hotmail.com
Key Words	Crohn’s disease; Inflammatory bowel disease; Risankizumab; Real-world evidence; Interleukin-12/23
Core Tip	Risankizumab, a selective interleukin-23p19 inhibitor, emerges as a promising therapeutic option for patients with multirefractory Crohn’s disease. This multicenter real-world study of 205 patients demonstrates that risankizumab rapidly achieves clinical remission (49% at week 12) and maintains steroid-free remission in over 40% of patients throughout one-year follow-up. The excellent safety profile and high treatment persistence (> 90%) establish interleukin-23 blockade as a key strategy for patients with limited biologic alternatives in routine clinical practice.
Citation	Caballero-Mateos AM, Valdés-Delgado T, Olmedo-Martín R, Romero-Cara P, Martín-Rodríguez MDM, Lancho Muñoz A, Moreno-Barrueco M, Gijón-Villanova R, Fernández-Moreno N, Rodríguez-González FJ, Hernández-Martínez Á, Trapero-Martínez AM, Bejarano-García A, Benitez Cantero JM, Mata-Perdigón FJ, Sáez-Díaz A, Argüelles-Arias F. Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis. World J Gastroenterol 2026; In press

Received	2026-02-03 01:54
Peer-Review Started	2026-02-03 01:57
First Decision by Editorial Office Director	2026-02-14 07:54
Return for Revision	2026-02-14 07:54
Revised	2026-02-27 13:14
Publication Fee Transferred
Second Decision by Editor	2026-04-13 02:42
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-04-13 08:31
Articles in Press	2026-04-13 08:31
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com